Related Experiment Videos
Somatostatin does not alter insulin-mediated glucose disposal
The Journal of Clinical Endocrinology and Metabolism
|August 1, 1987
Summary
Somatostatin (SRIH) infusion does not enhance insulin action or glucose disposal in healthy young adults. This study found no significant difference in insulin-mediated glucose disposal with or without SRIH.
Area of Science:
- Endocrinology
- Metabolism
Background:
- Somatostatin (SRIH) is a hormone that inhibits the release of various endocrine and exocrine secretions.
- Its precise role in modulating insulin action and glucose metabolism requires further elucidation.
Purpose of the Study:
- To investigate the effect of somatostatin (SRIH) infusion on insulin-mediated glucose disposal (Rd) in normal young subjects.
- To determine the influence of SRIH on insulin action under physiological conditions.
Main Methods:
- Paired 3-hour euglycemic insulin clamp studies were conducted in 8 healthy young subjects.
- Subjects received either insulin alone or insulin with SRIH and glucagon replacement.
Main Results:
- Basal and steady-state plasma glucose, insulin, glucagon, and GH concentrations were similar between groups.
- Hepatic glucose production and insulin-mediated glucose disposal (Rd) were not significantly different with SRIH infusion.
Conclusions:
- Somatostatin (SRIH) infusion, even with glucagon replacement, does not augment insulin-mediated glucose disposal in normal young subjects.
- SRIH does not appear to significantly alter insulin action at physiological insulin levels in this population.